Kansas City health leaders announce new integrated theranostics research and treatment center
University of Kansas Health System
Kansas City, Kan.
John Corbin receives theranostics treatment. Photo courtesy of the University of Kansas Health System.
The University of Kansas Health System, the University of Kansas Medical Center, Children’s Mercy and BAMF Health announced in February 2026 their collaboration on a new fully integrated theranostics research and treatment center — one of the first of its kind in the nation. The center will unite diagnostics, molecular imaging, radiopharmaceutical production and targeted therapies under one coordinated platform to provide more precise, less invasive care.
A key feature of the initiative is its strong emphasis on pediatric access. While theranostics is currently used mainly in adult care, Children’s Mercy is among the first pediatric systems to invest early, ensuring children benefit from emerging therapies without delay. Leaders said the partnership strengthens clinical trial capacity and accelerates the development of breakthrough treatments for patients across Kansas City and beyond.
“Theranostics is the next forefront of precision medical care and research,” said Bob Page, president and CEO of The University of Kansas Health System. “This collaboration will advance both discovery and treatment, while driving investment in the Kansas City region as a destination for healthcare and research.”